• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Doximity Announces Fiscal 2025 Second Quarter Financial Results

    11/7/24 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology
    Get the next $DOCS alert in real time by email

    Total revenues of $136.8 million, up 20% year-over-year

    Net income growth of 44% and adjusted EBITDA growth of 41% year-over-year

    Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 second quarter ended September 30, 2024.

    "Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescribers," said Jeff Tangney, co-founder and CEO of Doximity. "We're proud to help physicians save time, so they can provide better care for their patients."

    Fiscal 2025 Second Quarter Financial Highlights

    All comparisons, unless otherwise noted, are to the three months ended September 30, 2023.

    • Revenue: Revenue of $136.8 million, versus $113.6 million, an increase of 20% year-over-year.
    • Net income and non-GAAP net income: Net income of $44.2 million, versus $30.6 million, representing a margin of 32.3%, versus 26.9%. Non-GAAP net income of $61.1 million, versus $45.6 million, representing a margin of 44.7%, versus 40.1%.
    • Adjusted EBITDA: Adjusted EBITDA of $76.1 million, versus $54.2 million, an increase of 41% year-over-year, representing adjusted EBITDA margins of 55.7%, versus 47.7%.
    • Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.22, versus $0.15, while non-GAAP diluted net income per share was $0.30, versus $0.22.
    • Operating cash flow and free cash flow: Operating cash flow of $68.3 million, versus $12.9 million, an increase of 430% year-over-year, and free cash flow of $66.8 million, versus $11.6 million, an increase of 475% year-over-year.

    Financial Outlook

    Doximity is providing guidance for its fiscal third quarter ending December 31, 2024 as follows:

    • Revenue between $152 million and $153 million.
    • Adjusted EBITDA between $83 million and $84 million.

    Doximity is updating guidance for its fiscal year ending March 31, 2025 as follows:

    • Revenue between $535 million and $540 million.
    • Adjusted EBITDA between $274 million and $279 million.

    Conference Call Information

    Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company's Investor Relations page shortly after the call.

    About Doximity

    Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

    Forward-Looking Statements

    Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members' interests; (vi) breaches in our security measures or unauthorized access to members' data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management's beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    DOXIMITY, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)

     

    September 30, 2024

     

    March 31, 2024

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    184,248

     

    $

    96,785

     

    Marketable securities

     

    621,310

     

     

    666,115

     

    Accounts receivable, net

     

    124,793

     

     

    101,332

     

    Prepaid expenses and other current assets

     

    27,361

     

     

    48,709

     

    Total current assets

     

    957,712

     

     

    912,941

     

    Property and equipment, net

     

    12,818

     

     

    12,318

     

    Deferred income tax assets

     

    43,761

     

     

    45,068

     

    Operating lease right-of-use assets

     

    9,774

     

     

    12,332

     

    Intangible assets, net

     

    25,195

     

     

    27,317

     

    Goodwill

     

    67,940

     

     

    67,940

     

    Other assets

     

    1,316

     

     

    1,458

     

    Total assets

    $

    1,118,516

     

    $

    1,079,374

     

    Liabilities and Stockholders' Equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    2,770

     

    $

    2,253

     

    Accrued expenses and other current liabilities

     

    33,540

     

     

    43,703

     

    Deferred revenue, current

     

    93,751

     

     

    99,145

     

    Operating lease liabilities, current

     

    2,222

     

     

    2,149

     

    Total current liabilities

     

    132,283

     

     

    147,250

     

    Deferred revenue, non-current

     

    148

     

     

    211

     

    Operating lease liabilities, non-current

     

    11,269

     

     

    12,397

     

    Contingent earn-out consideration liability, non-current

     

    5,469

     

     

    10,895

     

    Other liabilities, non-current

     

    8,151

     

     

    7,224

     

    Total liabilities

     

    157,320

     

     

    177,977

     

    Stockholders' Equity

     

     

     

    Preferred stock

     

    —

     

     

    —

     

    Common stock

     

    187

     

     

    187

     

    Additional paid-in capital

     

    863,113

     

     

    823,885

     

    Accumulated other comprehensive income (loss)

     

    2,676

     

     

    (2,664

    )

    Retained earnings

     

    95,220

     

     

    79,989

     

    Total stockholders' equity

     

    961,196

     

     

    901,397

     

    Total liabilities and stockholders' equity

    $

    1,118,516

     

    $

    1,079,374

     

    DOXIMITY, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)

     

     

    Three Months Ended September 30,

     

    Six Months Ended September 30,

     

    2024

     

    2023

     

    2024

     

    2023

    Revenue

    $

    136,832

     

    $

    113,612

     

    $

    263,508

     

    $

    222,081

    Cost of revenue(1)

     

    13,676

     

     

    12,759

     

     

    27,226

     

     

    25,912

    Gross profit

     

    123,156

     

     

    100,853

     

     

    236,282

     

     

    196,169

    Operating expenses(1):

     

     

     

     

     

     

     

    Research and development

     

    23,240

     

     

    19,958

     

     

    45,814

     

     

    41,889

    Sales and marketing

     

    34,367

     

     

    30,201

     

     

    69,611

     

     

    64,656

    General and administrative

     

    10,103

     

     

    8,966

     

     

    19,358

     

     

    18,213

    Restructuring and impairment charge

     

    2,304

     

     

    7,936

     

     

    2,304

     

     

    7,936

    Total operating expenses

     

    70,014

     

     

    67,061

     

     

    137,087

     

     

    132,694

    Income from operations

     

    53,142

     

     

    33,792

     

     

    99,195

     

     

    63,475

    Other income, net

     

    9,029

     

     

    5,903

     

     

    16,145

     

     

    10,742

    Income before income taxes

     

    62,171

     

     

    39,695

     

     

    115,340

     

     

    74,217

    Provision for income taxes

     

    18,017

     

     

    9,093

     

     

    29,809

     

     

    15,209

    Net income

    $

    44,154

     

    $

    30,602

     

    $

    85,531

     

    $

    59,008

    Net income per share attributable to Class A and Class B common stockholders:

     

     

     

     

     

     

     

    Basic

    $

    0.24

     

    $

    0.16

     

    $

    0.46

     

    $

    0.30

    Diluted

    $

    0.22

     

    $

    0.15

     

    $

    0.43

     

    $

    0.28

    Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

     

     

     

     

     

     

     

    Basic

     

    186,252

     

     

    193,112

     

     

    185,933

     

     

    193,813

    Diluted

     

    200,407

     

     

    209,014

     

     

    199,818

     

     

    210,681

    (1) Costs and expenses include stock-based compensation expense as follows (in thousands):

     

    Three Months Ended September 30,

     

    Six Months Ended September 30,

     

    2024

     

    2023

     

    2024

     

    2023

    Cost of revenue

    $

    2,661

     

    $

    2,278

     

    $

    5,555

     

    $

    4,739

    Research and development

     

    5,447

     

     

    2,538

     

     

    10,131

     

     

    5,794

    Sales and marketing

     

    6,808

     

     

    2,697

     

     

    13,394

     

     

    8,692

    General and administrative

     

    2,952

     

     

    2,288

     

     

    5,878

     

     

    4,577

    Restructuring

     

    —

     

     

    3,646

     

     

    —

     

     

    3,646

    Total stock-based compensation expense

    $

    17,868

     

    $

    13,447

     

    $

    34,958

     

    $

    27,448

    DOXIMITY, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

    (unaudited)

     

     

    Three Months Ended September 30,

     

    Six Months Ended September 30,

     

    2024

     

    2023

     

    2024

     

    2023

    Cash flows from operating activities

     

     

     

     

     

     

     

    Net income

    $

    44,154

     

     

    $

    30,602

     

     

    $

    85,531

     

     

    $

    59,008

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

     

     

     

     

    Depreciation and amortization

     

    2,613

     

     

     

    2,604

     

     

     

    5,175

     

     

     

    5,208

     

    Deferred income taxes

     

    204

     

     

     

    —

     

     

     

    204

     

     

     

    —

     

    Stock-based compensation, net of amounts capitalized

     

    17,868

     

     

     

    13,447

     

     

     

    34,958

     

     

     

    27,448

     

    Non-cash lease expense

     

    470

     

     

     

    540

     

     

     

    951

     

     

     

    1,077

     

    Accretion of discount on marketable securities, net

     

    (3,008

    )

     

     

    (1,495

    )

     

     

    (5,368

    )

     

     

    (1,794

    )

    Amortization of deferred contract costs

     

    2,033

     

     

     

    2,063

     

     

     

    4,759

     

     

     

    4,730

     

    Impairment of long-lived assets

     

    2,304

     

     

     

    —

     

     

     

    2,304

     

     

     

    —

     

    Other

     

    414

     

     

     

    6

     

     

     

    (122

    )

     

     

    127

     

    Changes in operating assets and liabilities:

     

     

     

     

     

     

     

    Accounts receivable

     

    (4,106

    )

     

     

    (4,388

    )

     

     

    (23,478

    )

     

     

    9,644

     

    Prepaid expenses and other assets

     

    9,488

     

     

     

    (13,093

    )

     

     

    19,948

     

     

     

    (10,504

    )

    Deferred contract costs

     

    (1,785

    )

     

     

    (1,238

    )

     

     

    (3,216

    )

     

     

    (2,448

    )

    Accounts payable, accrued expenses and other liabilities

     

    7,396

     

     

     

    (8,740

    )

     

     

    (5,546

    )

     

     

    (8,063

    )

    Deferred revenue

     

    (9,161

    )

     

     

    (6,831

    )

     

     

    (5,457

    )

     

     

    (13,753

    )

    Operating lease liabilities

     

    (538

    )

     

     

    (579

    )

     

     

    (1,054

    )

     

     

    (582

    )

    Net cash provided by operating activities

     

    68,346

     

     

     

    12,898

     

     

     

    109,589

     

     

     

    70,098

     

    Cash flows from investing activities

     

     

     

     

     

     

     

    Purchases of property and equipment

     

    —

     

     

     

    (41

    )

     

     

    —

     

     

     

    (111

    )

    Internal-use software development costs

     

    (1,543

    )

     

     

    (1,238

    )

     

     

    (3,247

    )

     

     

    (2,732

    )

    Purchases of marketable securities

     

    (197,395

    )

     

     

    (144,942

    )

     

     

    (367,808

    )

     

     

    (180,226

    )

    Maturities of marketable securities

     

    215,855

     

     

     

    96,119

     

     

     

    417,913

     

     

     

    212,768

     

    Sales of marketable securities

     

    7,241

     

     

     

    —

     

     

     

    7,241

     

     

     

    37,525

     

    Net cash provided by (used in) investing activities

     

    24,158

     

     

     

    (50,102

    )

     

     

    54,099

     

     

     

    67,224

     

    Cash flows from financing activities

     

     

     

     

     

     

     

    Proceeds from issuance of common stock upon exercise of stock options and common stock warrants

     

    7,692

     

     

     

    3,933

     

     

     

    10,243

     

     

     

    7,218

     

    Proceeds from issuance of common stock in connection with the employee stock purchase plan

     

    1,422

     

     

     

    1,494

     

     

     

    1,422

     

     

     

    1,494

     

    Taxes paid related to net share settlement of equity awards

     

    (5,828

    )

     

     

    (2,120

    )

     

     

    (8,222

    )

     

     

    (4,084

    )

    Repurchase of common stock

     

    (22,984

    )

     

     

    (164,429

    )

     

     

    (74,198

    )

     

     

    (186,184

    )

    Payment of contingent consideration related to a business combination

     

    —

     

     

     

    —

     

     

     

    (5,470

    )

     

     

    (5,390

    )

    Net cash used in financing activities

     

    (19,698

    )

     

     

    (161,122

    )

     

     

    (76,225

    )

     

     

    (186,946

    )

    Net increase (decrease) in cash and cash equivalents

     

    72,806

     

     

     

    (198,326

    )

     

     

    87,463

     

     

     

    (49,624

    )

    Cash and cash equivalents, beginning of period

     

    111,442

     

     

     

    306,729

     

     

     

    96,785

     

     

     

    158,027

     

    Cash and cash equivalents, end of period

    $

    184,248

     

     

    $

    108,403

     

     

    $

    184,248

     

     

    $

    108,403

     

    Supplemental disclosures of cash flow information

     

     

     

     

     

     

     

    Cash paid for taxes, net of refunds

    $

    9,078

     

     

    $

    29,438

     

     

    $

    21,985

     

     

    $

    29,438

     

    Non-GAAP Financial Measures

    To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance:

    • Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of stock-based compensation expense, amortization of acquired intangible assets, change in fair value of contingent earn-out consideration liability, and restructuring and impairment charge from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
    • Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for stock-based compensation expense, change in fair value of contingent earn-out consideration liability, restructuring and impairment charge, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
    • Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.

    We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

    Key Business Metrics

    • Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month ("TTM") subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.
    • Customers with trailing 12-month subscription revenue greater than $500,000: The number of customers with TTM subscription revenue greater than $500,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

    Reconciliation of GAAP to Non-GAAP Financial Measures

    The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

     

    Three Months Ended September 30,

     

    Six Months Ended September 30,

     

    2024

     

    2023

     

    2024

     

    2023

     

    (unaudited)

     

    (in thousands, except percentages)

    Net income

    $

    44,154

     

     

    $

    30,602

     

     

    $

    85,531

     

     

    $

    59,008

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation

     

    17,868

     

     

     

    9,801

     

     

     

    34,958

     

     

     

    23,802

     

    Depreciation and amortization

     

    2,613

     

     

     

    2,604

     

     

     

    5,175

     

     

     

    5,208

     

    Provision for income taxes

     

    18,017

     

     

     

    9,093

     

     

     

    29,809

     

     

     

    15,209

     

    Restructuring and impairment charge

     

    2,304

     

     

     

    7,936

     

     

     

    2,304

     

     

     

    7,936

     

    Change in fair value of contingent earn-out consideration liability

     

    221

     

     

     

    47

     

     

     

    423

     

     

     

    316

     

    Other income, net

     

    (9,029

    )

     

     

    (5,903

    )

     

     

    (16,145

    )

     

     

    (10,742

    )

    Adjusted EBITDA

    $

    76,148

     

     

    $

    54,180

     

     

    $

    142,055

     

     

    $

    100,737

     

     

     

     

     

     

     

     

     

    Revenue

    $

    136,832

     

     

    $

    113,612

     

     

    $

    263,508

     

     

    $

    222,081

     

    Net income margin

     

    32.3

    %

     

     

    26.9

    %

     

     

    32.5

    %

     

     

    26.6

    %

    Adjusted EBITDA margin

     

    55.7

    %

     

     

    47.7

    %

     

     

    53.9

    %

     

     

    45.4

    %

     

    Three Months Ended September 30,

     

    Six Months Ended September 30,

     

    2024

     

    2023

     

    2024

     

    2023

     

    (unaudited)

     

    (in thousands)

    Net cash provided by operating activities

    $

    68,346

     

     

    $

    12,898

     

     

    $

    109,589

     

     

    $

    70,098

     

    Purchases of property and equipment

     

    —

     

     

     

    (41

    )

     

     

    —

     

     

     

    (111

    )

    Internal-use software development costs

     

    (1,543

    )

     

     

    (1,238

    )

     

     

    (3,247

    )

     

     

    (2,732

    )

    Free cash flow

    $

    66,803

     

     

    $

    11,619

     

     

    $

    106,342

     

     

    $

    67,255

     

    Other cash flow components:

     

     

     

     

     

     

     

    Net cash provided by (used in) investing activities

    $

    24,158

     

     

    $

    (50,102

    )

     

    $

    54,099

     

     

    $

    67,224

     

    Net cash used in financing activities

    $

    (19,698

    )

     

    $

    (161,122

    )

     

    $

    (76,225

    )

     

    $

    (186,946

    )

     

    Three Months Ended September 30,

     

    Six Months Ended September 30,

     

    2024

     

    2023

     

    2024

     

    2023

     

    (unaudited)

     

    (in thousands, except per share data and percentages)

    GAAP cost of revenue

    $

    13,676

     

     

    $

    12,759

     

     

    $

    27,226

     

     

    $

    25,912

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation

     

    (2,661

    )

     

     

    (2,278

    )

     

     

    (5,555

    )

     

     

    (4,739

    )

    Amortization of acquired intangibles

     

    —

     

     

     

    (137

    )

     

     

    —

     

     

     

    (274

    )

    Non-GAAP cost of revenue

    $

    11,015

     

     

    $

    10,344

     

     

    $

    21,671

     

     

    $

    20,899

     

     

     

     

     

     

     

     

     

    GAAP gross profit

    $

    123,156

     

     

    $

    100,853

     

     

    $

    236,282

     

     

    $

    196,169

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation

     

    2,661

     

     

     

    2,278

     

     

     

    5,555

     

     

     

    4,739

     

    Amortization of acquired intangibles

     

    —

     

     

     

    137

     

     

     

    —

     

     

     

    274

     

    Non-GAAP gross profit

    $

    125,817

     

     

    $

    103,268

     

     

    $

    241,837

     

     

    $

    201,182

     

     

     

     

     

     

     

     

     

    GAAP gross margin

     

    90.0

    %

     

     

    88.8

    %

     

     

    89.7

    %

     

     

    88.3

    %

    Non-GAAP gross margin

     

    91.9

    %

     

     

    90.9

    %

     

     

    91.8

    %

     

     

    90.6

    %

     

     

     

     

     

     

     

     

    GAAP research and development expense

    $

    23,240

     

     

    $

    19,958

     

     

    $

    45,814

     

     

    $

    41,889

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation

     

    (5,447

    )

     

     

    (2,538

    )

     

     

    (10,131

    )

     

     

    (5,794

    )

    Non-GAAP research and development expense

    $

    17,793

     

     

    $

    17,420

     

     

    $

    35,683

     

     

    $

    36,095

     

     

     

     

     

     

     

     

     

    GAAP sales and marketing expense

    $

    34,367

     

     

    $

    30,201

     

     

    $

    69,611

     

     

    $

    64,656

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation

     

    (6,808

    )

     

     

    (2,697

    )

     

     

    (13,394

    )

     

     

    (8,692

    )

    Amortization of acquired intangibles

     

    (1,061

    )

     

     

    (1,061

    )

     

     

    (2,122

    )

     

     

    (2,122

    )

    Change in fair value of contingent earn-out consideration liability

     

    (221

    )

     

     

    (47

    )

     

     

    (423

    )

     

     

    (316

    )

    Non-GAAP sales and marketing expense

    $

    26,277

     

     

    $

    26,396

     

     

    $

    53,672

     

     

    $

    53,526

     

     

     

     

     

     

     

     

     

    GAAP general and administrative expense

    $

    10,103

     

     

    $

    8,966

     

     

    $

    19,358

     

     

    $

    18,213

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation

     

    (2,952

    )

     

     

    (2,288

    )

     

     

    (5,878

    )

     

     

    (4,577

    )

    Non-GAAP general and administrative expense

    $

    7,151

     

     

    $

    6,678

     

     

    $

    13,480

     

     

    $

    13,636

     

     

     

     

     

     

     

     

     

    GAAP operating expense

    $

    70,014

     

     

    $

    67,061

     

     

    $

    137,087

     

     

    $

    132,694

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation

     

    (15,207

    )

     

     

    (7,523

    )

     

     

    (29,403

    )

     

     

    (19,063

    )

    Amortization of acquired intangibles

     

    (1,061

    )

     

     

    (1,061

    )

     

     

    (2,122

    )

     

     

    (2,122

    )

    Change in fair value of contingent earn-out consideration liability

     

    (221

    )

     

     

    (47

    )

     

     

    (423

    )

     

     

    (316

    )

    Restructuring and impairment charge

     

    (2,304

    )

     

     

    (7,936

    )

     

     

    (2,304

    )

     

     

    (7,936

    )

    Non-GAAP operating expense

    $

    51,221

     

     

    $

    50,494

     

     

    $

    102,835

     

     

    $

    103,257

     

     

     

     

     

     

     

     

     

    GAAP operating income

    $

    53,142

     

     

    $

    33,792

     

     

    $

    99,195

     

     

    $

    63,475

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation

     

    17,868

     

     

     

    9,801

     

     

     

    34,958

     

     

     

    23,802

     

    Amortization of acquired intangibles

     

    1,061

     

     

     

    1,198

     

     

     

    2,122

     

     

     

    2,396

     

    Change in fair value of contingent earn-out consideration liability

     

    221

     

     

     

    47

     

     

     

    423

     

     

     

    316

     

    Restructuring and impairment charge

     

    2,304

     

     

     

    7,936

     

     

     

    2,304

     

     

     

    7,936

     

    Non-GAAP operating income

    $

    74,596

     

     

    $

    52,774

     

     

    $

    139,002

     

     

    $

    97,925

     

     

     

     

     

     

     

     

     

    GAAP net income

    $

    44,154

     

     

    $

    30,602

     

     

    $

    85,531

     

     

    $

    59,008

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation

     

    17,868

     

     

     

    9,801

     

     

     

    34,958

     

     

     

    23,802

     

    Amortization of acquired intangibles

     

    1,061

     

     

     

    1,198

     

     

     

    2,122

     

     

     

    2,396

     

    Change in fair value of contingent earn-out consideration liability

     

    221

     

     

     

    47

     

     

     

    423

     

     

     

    316

     

    Restructuring and impairment charge

     

    2,304

     

     

     

    7,936

     

     

     

    2,304

     

     

     

    7,936

     

    Income tax effect of non-GAAP adjustments (1)

     

    (4,505

    )

     

     

    (3,986

    )

     

     

    (8,359

    )

     

     

    (7,235

    )

    Non-GAAP net income

    $

    61,103

     

     

    $

    45,598

     

     

    $

    116,979

     

     

    $

    86,223

     

    Non-GAAP net income margin

     

    44.7

    %

     

     

    40.1

    %

     

     

    44.4

    %

     

     

    38.8

    %

     

     

     

     

     

     

     

     

    Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

     

     

     

     

     

     

     

    Basic

     

    186,252

     

     

     

    193,112

     

     

     

    185,933

     

     

     

    193,813

     

    Diluted

     

    200,407

     

     

     

    209,014

     

     

     

    199,818

     

     

     

    210,681

     

     

     

     

     

     

     

     

     

    Non-GAAP net income per share attributable to Class A and Class B stockholders:

     

     

     

     

     

     

     

    Basic

    $

    0.33

     

     

    $

    0.24

     

     

    $

    0.63

     

     

    $

    0.44

     

    Diluted

    $

    0.30

     

     

    $

    0.22

     

     

    $

    0.59

     

     

    $

    0.41

     

    (1) For the three and six months ended September 30, 2024 and 2023, management used an estimated annual effective non-GAAP tax rate of 21.0%.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241107362244/en/

    Get the next $DOCS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DOCS

    DatePrice TargetRatingAnalyst
    2/7/2025$31.00 → $78.00Neutral → Overweight
    Piper Sandler
    2/7/2025$60.00 → $90.00Market Perform → Outperform
    Leerink Partners
    12/20/2024$55.00Equal-Weight
    Stephens
    12/4/2024$55.00Neutral
    Mizuho
    11/15/2024$58.00Neutral
    Goldman
    11/14/2024$33.00 → $53.00Underweight → Equal-Weight
    Morgan Stanley
    11/13/2024$40.00 → $60.00Buy → Hold
    Canaccord Genuity
    11/8/2024$19.00 → $41.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $DOCS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Doximity to Release Fiscal 2025 Fourth Quarter and Full Year Results on May 15, 2025

      Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 after market close on May 15, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members

      4/24/25 4:01:00 PM ET
      $DOCS
      EDP Services
      Technology
    • Doximity to Participate in the Raymond James 46th Annual Institutional Investors Conference

      Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that Anna Bryson, CFO, will present at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025, at 10:25 a.m. Eastern Time/7:25 a.m. Pacific Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and rese

      2/13/25 4:29:00 PM ET
      $DOCS
      EDP Services
      Technology
    • Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fourth Consecutive Year

      Earns A-level ratings in all categories Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer has been named 2025 Best in KLAS in the Video Conferencing Platforms segment. This is the fourth consecutive year that Doximity has earned the top position. In addition to securing the #1 spot, Doximity received A-level ratings in all categories, including operations, product, relationship, value, culture, and loyalty. These ratings, which are based on live interviews with over 80 health system leaders and their staff, reinforce Doximity's leadership in delivering a reliable, easy-to-use virtual care platform. "We're hono

      2/6/25 4:02:00 PM ET
      $DOCS
      EDP Services
      Technology

    $DOCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Doximity upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Doximity from Neutral to Overweight and set a new price target of $78.00 from $31.00 previously

      2/7/25 9:03:46 AM ET
      $DOCS
      EDP Services
      Technology
    • Doximity upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Doximity from Market Perform to Outperform and set a new price target of $90.00 from $60.00 previously

      2/7/25 6:59:36 AM ET
      $DOCS
      EDP Services
      Technology
    • Stephens initiated coverage on Doximity with a new price target

      Stephens initiated coverage of Doximity with a rating of Equal-Weight and set a new price target of $55.00

      12/20/24 7:32:05 AM ET
      $DOCS
      EDP Services
      Technology

    $DOCS
    Financials

    Live finance-specific insights

    See more
    • Doximity to Release Fiscal 2025 Fourth Quarter and Full Year Results on May 15, 2025

      Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 after market close on May 15, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members

      4/24/25 4:01:00 PM ET
      $DOCS
      EDP Services
      Technology
    • Doximity Announces Fiscal 2025 Third Quarter Financial Results

      Total revenues of $168.6 million, up 25% year-over-year Net income growth of 57% and adjusted EBITDA growth of 39% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 third quarter ended December 31, 2024. "We're proud to deliver another quarter of record engagement in Q3, with over 610,000 unique providers using our clinical workflow tools," said Jeff Tangney, co-founder and CEO of Doximity. "Our AI tools grew the fastest last quarter, up 60% over the prior quarter, while our newsfeed surpassed more than one million unique providers." Fiscal 2025 Third Quarter Financial Highlights All com

      2/6/25 4:01:00 PM ET
      $DOCS
      EDP Services
      Technology
    • Doximity to Release Fiscal 2025 Third Quarter Results on February 6, 2025

      Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter ended December 31, 2024 after market close on February 6, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members inclu

      1/16/25 4:01:00 PM ET
      $DOCS
      EDP Services
      Technology

    $DOCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wampler Kira Scherer converted options into 2,000 shares and sold $113,853 worth of shares (2,000 units at $56.93) (SEC Form 4)

      4 - Doximity, Inc. (0001516513) (Issuer)

      5/2/25 4:19:42 PM ET
      $DOCS
      EDP Services
      Technology
    • Chief Financial Officer Bryson Anna converted options into 95,000 shares and sold $5,575,235 worth of shares (95,000 units at $58.69) (SEC Form 4)

      4 - Doximity, Inc. (0001516513) (Issuer)

      5/2/25 4:19:07 PM ET
      $DOCS
      EDP Services
      Technology
    • Chief Financial Officer Bryson Anna converted options into 32,900 shares, increasing direct ownership by 10% to 357,165 units (SEC Form 4)

      4 - Doximity, Inc. (0001516513) (Issuer)

      4/22/25 4:14:03 PM ET
      $DOCS
      EDP Services
      Technology

    $DOCS
    Leadership Updates

    Live Leadership Updates

    See more
    • Mendaera Closes $73M Series B Financing to Scale Robotics and AI Across Mainstream Medical Procedures

      With its first-of-its-kind platform, Mendaera is pioneering a new category in medical robotics Mendaera, Inc., a Silicon Valley-based healthcare technology company developing a handheld robotic interventional platform, announced today the close of $73 million in Series B funding led by Threshold Ventures, with participation from investors including Lux Capital, PFM Health Sciences, and Fred Moll (founder of Intuitive Surgical and Auris Health). The financing will further Mendaera's efforts to scale robotics and AI across mainstream medical procedures. The healthcare system is facing an increasing supply and demand crisis, where the ability to consistently deliver high-quality care to pati

      9/26/24 6:05:00 AM ET
      $DOCS
      $RELY
      $LVGO
      EDP Services
      Technology
      Business Services
      Consumer Discretionary
    • Doximity Appoints Phoebe Yang to Its Board of Directors

      Experienced director and executive brings health system and cloud expertise SAN FRANCISCO, Aug. 4, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced the appointment of Phoebe L. Yang to its Board of Directors. Ms. Yang has been General Manager at Amazon Web Services, Healthcare, and a member of the board of directors for CommonSpirit Health, one of the largest U.S. health systems. Ms. Yang is a long-time member of the Council on Foreign Relations, and has served as an appointee in two Presidential Administrations. In 2021, she was named one of Modern Healthcare's Top 100 Most Influential People in Healthcare and one

      8/4/22 4:02:00 PM ET
      $DOCS
      EDP Services
      Technology

    $DOCS
    SEC Filings

    See more
    • SEC Form 144 filed by Doximity Inc.

      144 - Doximity, Inc. (0001516513) (Subject)

      5/2/25 4:06:18 PM ET
      $DOCS
      EDP Services
      Technology
    • Amendment: SEC Form SCHEDULE 13G/A filed by Doximity Inc.

      SCHEDULE 13G/A - Doximity, Inc. (0001516513) (Subject)

      3/7/25 10:01:30 AM ET
      $DOCS
      EDP Services
      Technology
    • Amendment: SEC Form SCHEDULE 13G/A filed by Doximity Inc.

      SCHEDULE 13G/A - Doximity, Inc. (0001516513) (Subject)

      2/13/25 4:01:03 PM ET
      $DOCS
      EDP Services
      Technology

    $DOCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Doximity Inc.

      SC 13G/A - Doximity, Inc. (0001516513) (Subject)

      11/14/24 5:22:01 PM ET
      $DOCS
      EDP Services
      Technology
    • SEC Form SC 13G filed by Doximity Inc.

      SC 13G - Doximity, Inc. (0001516513) (Subject)

      11/14/24 11:42:53 AM ET
      $DOCS
      EDP Services
      Technology
    • SEC Form SC 13G filed by Doximity Inc.

      SC 13G - Doximity, Inc. (0001516513) (Subject)

      11/12/24 9:55:17 AM ET
      $DOCS
      EDP Services
      Technology